Lymphokine-activated killer (LAK) cells generated by cultivation of C57BL/6 mouse spleen cells in the presence of recombinant interleukin-2 were transferred into natural killer (NK) cell-deficient suckling mouse recipients. These mice were then challenged with either murine cytomegalovirus (MCMV) or lymphocytic choriomeningitis (LCMV) and sacrificed 3 days later. No interleukin 2 infusions were given. Mice receiving as few as 5 x 1 LAK cells had several 100-fold decreases in spleen MCMV titers as compared with untreated mice. This treatment had no effect on spleen LCMV titers. The LAK cell cultures contained 10 to 17% NK 1.1+, 50 to 55% Lyt-2+, and 33 to 50% immunoglobulin D+ cells. 
Lymphokine-activated killer (LAK) cells are culture-generated effector cells capable of nonspecifically killing tumor cells (13) and of mediating an antineoplastic effect in vivo against established solid tumors (24) . The phenotype of the cells mediating these effects has been controversial, but several laboratories (18, 21, 27, 29) now agree that most but not all of the in vitro cytotoxic function of both human and mouse LAK cells is attributable to a population of cells expressing the natural killer (NK) cell phenotype. Most killing in mouse LAK cultures is mediated by NK 1.1+, asialo GM1+, Lyt-2-, la-, and Ly-5+ cells, identical to the NK cell phenotype. The cytotoxic activity mediated by Lyt-2+ effector cells in this system has been suggested to be due to polyclonal stimulation of cytotoxic T lymphocytes (CTL) (19) or to a unique cell type distinct from NK cells and classic CTL (1) .
NK cells become activated (17, 22, 36, 37) and proliferate (3) during virus infections, and there is evidence that they mediate an antiviral role during certain infections (reviewed in reference 35) . A small dose of antibody to asialo GM1, which selectively eliminates NK cell activity (14) , enhances virus replication and pathogenesis during mouse hepatitis virus, vaccinia virus, influenza virus, coxsackie virus B, and murine cytomegalovirus (MCMV) infections (9, 12, 31) but not lymphocytic choriomeningitis virus (LCMV) infection (9) . Adoptive transfer experiments with fresh spleen cells enriched for or depleted of NK cells have provided compel-ling evidence that NK cells exert a potent antiviral effect against MCMV, an NK cell-sensitive virus, but not against LCMV, an NK cell-resistant virus (5) .
Because of the therapeutic potential of LAK cells and theiri similarity to NK cells, we tested LAK cells in an adoptive transfer system for their ability to provide resistance to viral infections. Here we report that relatively low numbers of LAK Viruses. The Smith strain of MCMV (25) was prepared by intraperitoneal (i.p.) inoculation of BALB/c ByJ mice with 104 PFU. Salivary glands were harvested 2 to 3 weeks postinfection, homogenized in a 10% suspension in MEM, and cleared by centrifugation. Aliquots were stored at -70°C in 10% dimethyl sulfoxide. The Armstrong strain of LCMV used in these studies was grown in BHK cells (34) .
Cytotoxicity assay. The assay medium was RPMI 1640 supplemented with 0.1 M N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES) (Sigma Chemical Corp., St. Louis, Mo.) and the same additives listed above. The assay was performed as described previously (34) . Briefly, target cells labeled with 100 ,uCi of Na51CrO4 (New England Nuclear Corp., Boston, Mass.) for 1 h at 37°C were washed and mixed with various numbers of effector cells at 5 x 103 or 104 target cells per well. In some assays, target cells were treated for 12 to 16 h with 1,000 U of beta interferon (IFN) (Lee Biomolecular, San Diego, Calif.) per ml before being labeled. Medium instead of effector cells was added to the wells for spontaneous release determinations; for maximum release determinations, Nonidet P-40 was added. Plates were incubated for 4 to 13 h at 37°C with 5% CO2 in a humidified atmosphere. At the end of the incubation period, the plates were centrifuged at 200 x g for 5 min, and 0.1 ml of the supernatant was collected and counted for radioactivity in a Gamma 5500 counter (Beckman Instruments, Inc., Palo Alto, Calif.). Data were expressed as the percent specific release: 100 x [(experimental counts per minutespontaneous counts per minute)/(maximum counts per minute -spontaneous counts per minute)]. Spontaneous release of radioactivity was between 7 and 30%. Standard deviations of quadruplicate samples were <10% of the mean.
Virus titration. Spleens were homogenized to a 10% suspension in MEM and cleared by centrifugation. The supernatants were titrated by a plaque assay with mouse embryo fibroblasts and Vero cells for MCMV and LCMV, respectively, and virus titers were reported as PFU per spleen. Results were expressed as the geometric mean titer, i.e., the arithmetic average of the logarithm (base 10) of titers from four to six separately titrated individual mice plus or minus the standard error of the mean. When a sample had undetectable levels of virus, it was assigned a titer of <10 PFU, the lowest level of detection in our assay, and averaged with the rest of the samples. The resultant number was designated "less than." The P values represent the significance of the difference between the means of the designated sample and the control and were calculated by using Student's t test.
Antisera and FACS purification. Rabbit antiserum to immunoglobulin D (IgD) was obtained from David Parker (University of Massachusetts Medical Center, Worcester) (26) . Mouse monoclonal antibody to NK 1.1 (20) Generation of allospecific CTL. Allospecific CTL were generated as previously described (11) . Briefly, 1.5 x 107 BALB/c spleen cells were mixed with an equal number of gamma-irradiated (1,000 rads) C57BL/6 spleen cells in 10 ml of RPMI 1640 assay medium in 25-cm2 flasks and incubated for 5 to 6 days at 37°C with 5% CO2.
Adoptive transfers. C57BL/6 mice (3 to 5 days old) from several litters were pooled and randomly assigned to lactating mothers. Groups of four to six mice were given i.p. lengthened to 13 h (see Table 4 ). Lyt-2+ cells accounted for about 50% of the LAK population but were much less cytotoxic against YAC-1 cells and contained fewer LGL than NK 1.1+ cells ( 13 h because the magnitude of activity mediated by NK 1.1-and Lyt-2+ fractions was low. Both the NK 1.1+ and Lyt-2-fractions lysed the NK cell-sensitive YAC-1 targets much better than they did the NK cell-resistant P815 and L-929 targets (Table  4) , much like freshly isolated activated NK cells (2) . In contrast, Lyt-2+ and NK 1.1-fractions had similar cytotoxic activity against both NK cell-sensitive and NK cellresistant targets, suggesting that these cell types are different from NK 1.1+ LAK cells and freshly isolated activated NK cells.
Although the target specificities of the Lyt-2+ and NK 1.1+ LAK cells differed slightly, we questioned whether (39) and NK cell blasts (2) , and it represents a limitation in the usefulness of the antibody and complement depletion technique, especially with blast cells. We thus treated mice with positively and negatively selected FACS-purified populations of LAK cells, challenged them the next day with MCMV, and titrated their spleens for virus 3 days postinfection. Surprisingly, NK 1.1+ and NK 1.1-LAK cells were equally effective in mediating an antiviral effect against MCMV (Table 6 ). Similarly, Lyt-2+ and Lyt-2-LAK cell populations were both capable of protecting against MCMV (Table  6 ). In contrast, IgD-but not IgD+ LAK cells had antiviral activity (Table 6) . Collectively, the results show that the only LAK cell subpopulation which lacks the LGL morphology (IgD+ cells) is the only population incapable of mediating an antiviral effect in vivo.
DISCUSSION
The adoptive transfer studies reported here clearly demonstrate that LAK cells are capable of mediating a potent antiviral effect in vivo. As few as 2 x 105 LAK cells caused up to a 300-fold decrease in spleen MCMV titers (Table 6) and thus were several hundred times more effective in this regard than unpurified control spleen cells (Table 1) . The pattern of antiviral activity mediated by LAK cells in vivo was similar to that mediated by NK cells in that neither cell population had a protective effect against LCMV infections (5). The reason for this distinction among viruses may reflect differences in virus-induced cytopathic effects which result in differences in IFN-mediated protection of virus-infected target cells. IFN protects LCMV-infected but not MCMV- (Table 5) . We have not, however, ruled out the possibility that the antiviral effect in vivo is mediated by soluble factors instead of direct cell-to-cell cytotoxicity.
Since relatively few LAK cells were required for protection (in contrast to antitumor studies), it was possible to use FACS-purified LAK cells in adoptive transfer protocols to determine which cell population(s) was mediating the antiviral effect. We found that Lyt-2+, Lyt-2-, NK 1.1+, NK 1.1-and IgD-populations of cells protected equally well in our model. This was somewhat surprising because of our previous results showing that NK cells are required for the protection mediated in control fresh spleen cell adoptive transfer studies and that a lack of NK cells but not T cells in adult mice results in increases in MCMV synthesis early in infection (5). However, LAK cells are different from freshly isolated spleen cells in several ways, the most notable being that fresh Lyt-2+ naive spleen cells are not cytotoxic but that some Lyt-2+ LAK cells are (18, 19, 40) .
All the populations providing antiviral protection in vivo (NK 1.1+, NK 1.1-, Lyt-2+, Lyt-2-, and IgD-) included cytotoxic effector cells, although their efficiencies at mediating in vitro cytotoxicity against YAC-1 targets varied greatly (NK 1.1+ > IgD-> Lyt-2-> Lyt-2+ > NK 1.1-IgD+). However, our results (Table 4 ) and the results of Kalland et al. (18) show that the different effector cell populations have more comparable levels of activity against EL-4, P815, and L-929 targets, the so-called 'NK-resistant' targets, although NK (18, 21, 27, 29) , and data presented here and elsewhere (18) indicate that the populations are mutually exclusive (Table 4) . NK 1.1+ cells probably represent activated NK cells (which have a broad but well-defined hierarchical target cell range [2] ), based on their target cell range (Table 4) , presence of surface NK 1.1 (Table 2 ) (18, 19) , and reduced ability to lyse IFN-treated targets (Table 5 ). The Lyt-2+ population probably represents non-major histocompatibility complex-restricted CTL, based on its ability to lyse a broad range of targets, including syngeneic targets (Table 4 ) (18, 29) . This type of cell can be created in cultures by treating cloned allospecific CTL with high IL-2 concentrations, similar to those used in generating LAK cells (4) . The fact that these Lyt-2+ LAK cells lyse IFN-treated targets less efficiently than control targets (Table 5) shows that lysis in this case is not mediated by classic allospecific CTL, which lyse IFN-treated targets more efficiently than control targets, probably because of the increased expression of class I major histocompatibility complex antigens on the targets (7, 8) .
These results showing potent antiviral activity in vivo suggest that LAK cells may be useful as an effective antiviral therapy for some virus infections, such as human cytomegalovirus. There is currently no effective therapy for human cytomegalovirus infection, which is the major cause of death in patients with acquired immunodeficiency syndrome (23), the most common infectious cause of birth defects (15) , and
